Trukhina D A, Mamedova E O, Lapshina A M, Vasilyev E V, Tiulpakov A N, Belaya Zh E
Endocrinology Research Centre.
Endocrinology Research Centre; Research Centre for Medical Genetics.
Probl Endokrinol (Mosk). 2021 Oct 25;67(6):50-58. doi: 10.14341/probl12815.
Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal dominant disorder caused by mutations in the MEN1 gene, which encodes the menin protein. If a patient has the MEN 1 phenotype in the absence of mutations in the MEN1 gene, the condition is classified as a phenocopy of this syndrome. Although significant progress has been made in understanding the function of menin, its role in the oncogenesis of the endocrine glands is still being elucidated. Due to its key role in physiological and pathological processes, the assessment of the menin expression can provide valuable information.
to determine whether there are any differences in the expression of menin in the pituitary adenomas (PA) in patients with phenocopy of MEN 1 (phMEN 1) and genetically confirmed MEN 1 (gMEN 1) compared with their sporadic forms.
immunohistochemical assessment of the menin expression was carried out in PA of patients with gMEN 1, phMEN 1 and sporadic acromegaly (SA), surgically treated in 2008-2020. IHC was performed using antibodies to menin, PRL, GH, ACTH, FSH, TSH, Pit-1, T-box, ERA on previously prepared histological section.
The study included 35 samples of PA: gMEN 1 - 9 samples, phMEN 1 - 12 (somatotropinomas + PHPT); CA - 14 samples. The patients were comparable by gender, adenoma size, and drug intake. The gMEN 1 group differed from phMEN 1 and SA by age (p = 0.0005). In patients with gMEN 1, the expression of menin varied from no staining (5/9) to intense cytoplasm staining. Cytoplasmic expression of menin was mainly present (11/12) in the phMEN 1. In the SA group, there was no staining in 1 case; nuclear expression was detected in 6/14 cases. The phMEN 1 group showed significantly higher cytoplasmic expression of menin than the gMEN 1 group (p = 0.006). The gMEN 1 group also differed from the SA group (p = 0.012). There were no statistically significant differences between the phMEN 1 and SA groups (p = 0.049).
It was revealed that the menin expression, in general, is retained in phMEN 1 and SA groups, although with different localization in the cell structure (nucleus and / or cytoplasm). At the same time, the expression of menin varies greatly in patients with gMEN 1. According to the data obtained, it can be assumed that the pathogenesis of PA in phMEN 1 and SA may have similarities; however, there could be factors contributing to the appearance of several tumors of the endocrine glands in one person with phMEN 1. To understand this process, it is necessary to further study the genes associated with MEN 1, epigenetic factors, signaling pathways in which menin is involved.
多发性内分泌腺瘤1型(MEN 1)是一种罕见的常染色体显性疾病,由MEN1基因突变引起,该基因编码menin蛋白。如果患者在MEN1基因无突变的情况下具有MEN 1表型,则该病症被归类为该综合征的表型模拟。尽管在了解menin的功能方面已取得重大进展,但其在内分泌腺肿瘤发生中的作用仍在阐明之中。由于其在生理和病理过程中的关键作用,menin表达的评估可提供有价值的信息。
确定与散发性垂体腺瘤相比,MEN 1表型模拟(phMEN 1)患者和基因确诊的MEN 1(gMEN 1)患者的垂体腺瘤(PA)中menin的表达是否存在差异。
对2008年至2020年接受手术治疗的gMEN 1、phMEN 1和散发性肢端肥大症(SA)患者的PA进行menin表达的免疫组织化学评估。免疫组化使用针对menin、PRL、GH、ACTH、FSH、TSH、Pit-1、T-box、ERA的抗体,在先前制备的组织切片上进行。
该研究包括35例PA样本:gMEN 1 - 9例样本,phMEN 1 - 12例(生长激素瘤 + 原发性甲状旁腺功能亢进症);SA - 14例样本。患者在性别、腺瘤大小和药物摄入方面具有可比性。gMEN 1组与phMEN 1组和SA组在年龄上存在差异(p = 0.0005)。在gMEN 1患者中,menin的表达从无染色(5/9)到强烈的细胞质染色不等。menin的细胞质表达主要出现在(11/12)phMEN 1中。在SA组中,1例无染色;6/14例检测到核表达。phMEN 1组的menin细胞质表达明显高于gMEN 1组(p = 0.006)。gMEN 1组也与SA组不同(p = 0.012)。phMEN 1组和SA组之间无统计学显著差异(p = 0.049)。
结果显示,总体而言,phMEN 1组和SA组中menin的表达得以保留,尽管在细胞结构(细胞核和/或细胞质)中的定位不同。同时,gMEN 1患者中menin的表达差异很大。根据所获得的数据,可以假设phMEN 1和SA中PA的发病机制可能具有相似性;然而,可能存在导致phMEN 1患者出现多种内分泌腺肿瘤的因素。为了解这一过程,有必要进一步研究与MEN 1相关的基因、表观遗传因素以及menin所涉及的信号通路。